Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
SCYNEXIS (SCYX)
NASDAQ:SCYX
SCYNEXIS (SCYX) Stock Price & Analysis
1,471 Followers
SCYX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.35 - $3.87
Previous Close$2.62
Volume215.03K
Average Volume (3M)252.48K
Market Cap
$99.74M
Enterprise Value$13.91M
Total Cash (Recent Filing)$88.07M
Total Debt (Recent Filing)$3.00M
Price to Earnings (P/E)1.4
Beta1.63
Next Earnings
Aug 12, 2024EPS Estimate
-$0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.86
Shares Outstanding37,779,796
10 Day Avg. Volume519,199
30 Day Avg. Volume252,481
Standard Deviation0.23
R-Squared0.12
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.14
Price to Sales (P/S)19.44
Price to Cash Flow (P/CF)2.10
P/FCF Ratio2.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.10
Enterprise Value/Gross Profit2.73
Enterprise Value/Ebitda0.18
Forecast
1Y Price Target
$7.17Price Target Upside171.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
SCYNEXIS News
Bulls Say, Bears Say
Bulls Say
Drug Approval And Market PotentialScynexis gained FDA approval for Brexafemme (ibrexafungerp) for the treatment of vulvovaginal candidiasis (VVC) and recurrent vulvovaginal candidiasis (rVVC), bolstering its market presence in antifungal treatments.
Financial StabilityScynexis has a robust cash position to fund operations through 2025, underpinning its financial stability and supporting ongoing research and development activities.
Partnership And Potential RevenueThe exclusive licensing agreement with GlaxoSmithKline to commercialize and develop Brexafemme could result in a deal worth up to $593M plus tiered royalties, indicating a significant future revenue stream for Scynexis.
Bears Say
Clinical Trial DelaysThe MARIO study has been put on hold due to manufacturing delay/recall, potentially delaying important clinical outcomes.
Drug Contamination ConcernsThere are concerns regarding the clinical and commercial holds for ibrexa due to possible beta-lactam contamination.
Product Recall ImpactScynexis's recall of Brexafemme tablets due to manufacturing process issues could significantly disrupt the product's market availability.
---
Ownership Overview
15.14% Insiders
30.86% Mutual Funds
20.77% Other Institutional Investors
33.23% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SCYX FAQ
What was SCYNEXIS’s price range in the past 12 months?
SCYNEXIS lowest stock price was $1.35 and its highest was $3.87 in the past 12 months.
What is SCYNEXIS’s market cap?
Currently, no data Available
When is SCYNEXIS’s upcoming earnings report date?
SCYNEXIS’s upcoming earnings report date is Aug 12, 2024 which is in 83 days.
How were SCYNEXIS’s earnings last quarter?
SCYNEXIS released its earnings results on May 09, 2024. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of -$0.184 by $0.194.
Is SCYNEXIS overvalued?
According to Wall Street analysts SCYNEXIS’s price is currently Undervalued.
Does SCYNEXIS pay dividends?
SCYNEXIS does not currently pay dividends.
What is SCYNEXIS’s EPS estimate?
SCYNEXIS’s EPS estimate is -$0.15.
How many shares outstanding does SCYNEXIS have?
SCYNEXIS has 37,779,797 shares outstanding.
What happened to SCYNEXIS’s price movement after its last earnings report?
SCYNEXIS reported an EPS of $0.01 in its last earnings report, beating expectations of -$0.184. Following the earnings report the stock price went up 3.191%.
Which hedge fund is a major shareholder of SCYNEXIS?
Among the largest hedge funds holding SCYNEXIS’s share is Scion Asset Management. It holds SCYNEXIS’s shares valued at N/A.
---
SCYNEXIS Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.17 (171.59% Upside)
$7.17 (171.59% Upside)
Blogger Sentiment
Bullish
SCYX Sentiment 75%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 174.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.0%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.76%
12-Months-Change
Fundamentals
Return on Equity
458.59%
Trailing 12-Months
Asset Growth
68.22%
Trailing 12-Months
Company Description
SCYNEXIS
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
---
SCYX Company Deck
---
SCYX Earnings Call
Q4 2023
0:00 / 0:00
---
SCYX Stock 12 Month Forecast
Average Price Target
$7.17
▲(171.59% Upside)
Technical Analysis
Best Analysts Covering SCYX
1 Year
1 Year Success Rate
11/37 ratings generated profit
1 Year Average Return
-14.17%
reiterated a buy rating 12 days ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 29.73% of your transactions generating a profit, with an average return of -14.17% per trade.
---